Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Auto and banks lose favor
Tue, 13 Apr 01:30 pm

Weakness in the Indian markets continued during the last 2 hours of trade with major indices trading in the red. While buying interest was seen in the IT and the consumer durable space, stocks in the oil & gas, banking and auto space weighed down the indices.

BSE-Sensex is trading lower by 32 points while NSE-Nifty is trading 15 points below the dotted line. BSE-Midcap Index is down by 0.12% while the BSE-Smallcap index is trading 0.27% above yesterday’s closing. The rupee is trading at 44.54 to the US dollar

As per a leading financial daily, Glenmark Pharmaceuticals and GlaxoSmithKline (GSK) have entered into an out of court settlement over the launch of a generic version of Malarone, an anti-malaria drug brand. Under the terms of settlement, Glenmark will be able to sell its generic tablets by paying a royalty to GSK from 2QFY11. Under this settlement, Glenmark will get an exclusivity of sale in the US market for 180 days upon the patent expiry. However, benefit for the company will be limited as the drug generated only US$ 56 m in sales in CY2009. Glenmark registered sales of approximately US$ 170 m in FY2009. In the best case scenario this drug would yield about US$ 11 - 12 m in sales, adding about 5% to the company’s topline on an annualized basis.

As per a business daily, Corporation Bank is planning to raise Rs 20 bn in FY11 to meet incremental credit growth requirements. This amount would be raised via a combination of Tier-I and Tier-II capital. The bank has estimated that it would require Rs 50 bn over the next 2 years to fuel its balance sheet growth. For the balance Rs 30 bn, the bank is considering tapping the equity market via a rights issue or a follow-on public offer. The bank is targeting a loan growth of 25% during FY11 with a net interest margin in the range of 2.5% to 2.6%. The credit growth is seen coming from real estate, infrastructure, retail and SME segments. With this capital, the bank's capital adequacy ratio will improve and the bank will have adequate cash to lend when the demand for credit picks up.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Auto and banks lose favor". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.